TABLE 4.

Demographic and Clinical Features by Patient

No.	Age, years	Tumor Site	Stage	Primary Treatment	Adjuvant Treatment	Treatment for Recurrence	Status at Last Follow-up
1	17.8	Cervix	IB1	Cone biopsy	Vincristine, dactinomycin, and cyclophosphamide	NA	NED 23 mo after completion of therapy
2	12.5	Cervix	IB2	Cone biopsy	Vincristine, dactinomycin, and cyclophosphamide	NA	NED 6 mo after completion of therapy
3	33.3	Cervix	IB1	TAH and BSO	Cisplatin and doxorubicin. Treated immediately after surgery with whole- pelvic and intracavitary vaginal radiation to 45 Gy	Chemotherapy	Dead of complications related to neutropenic fever
4	49.3	Cervix and lower uterine segment	IB1	TAH and BSO	Cyclophosphamide, doxorubicin, vincristine, and dacarbazine. Radiation beginning 6 mo after diagnosis: 46 Gy delivered over 31 days	NA	Dead of parotid adenocarcinom a
5	51.9	Cervix	IB2	Cone biopsy	NA	NA	NED 19 mo after completion of therapy
6	2.9	Cervix and midposteri or vagina	IIA	Polypectomy	Vincristine, dactinomycin, and cyclophosphamide	NA	NED 35 mo after completion of therapy
7	12.7	Endocervix extending to vagina	IB2	VAC	TAH	NA	NED 121 mo after completion of therapy
8	17.3	Cervix	NA	Cone biopsy	Vincristine, doxorubicin, and cyclophosphamide	Refused chemotherapy	Dead of disease
9	34.2	Cervix	NA	VAC, FAC	Cone biopsy	Not known whether patient had recurrence	Dead of unknown cause
10	27.2	Cervix	IB2	Cone biopsy	NA	Refused chemotherapy	Alive with disease
11	18.4	Cervix	IB1	Cone biopsy, diagnostic laparoscopy	Vincristine, dactinomycin, and cyclophosphamide	NA	NED 4 mo after completion of therapy

NA, Not applicable – patient did not have recurrence; NED, no evidence of disease; TAH; total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; VAC, vincristine, dactinomycin, and cyclophosphamide; FAC, fluorouracil, doxorubicin, and cyclophosphamide.